Related Experiment Video

Updated: Aug 16, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K

Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and

Negin Farhadian1, Maryam Farhadian2, Mohammad Hossein Zamanian3,4

  • 1Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Immunopharmacology and Immunotoxicology
|December 20, 2022
PubMed

Insights

Sotrovimab treatment significantly reduced hospitalization, ICU admission, and mortality in solid organ transplant recipients with mild-to-moderate COVID-19. This monoclonal antibody therapy offers a protective strategy for this high-risk patient group.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Transplantation Medicine

Background:

  • Solid organ transplant recipients (SOTR) face elevated risks of severe COVID-19.
  • Effective treatment strategies are crucial for mitigating COVID-19 complications in SOTR.
  • Sotrovimab is investigated as a potential therapeutic agent for this vulnerable population.

Approach:

  • A systematic literature search identified studies on sotrovimab in SOTR with mild-to-moderate COVID-19.
  • A meta-analysis synthesized clinical outcomes from eligible studies.
  • Statistical analysis evaluated the effectiveness of sotrovimab compared to control groups.

Key Points:

  • Sotrovimab administration was associated with a significantly lower likelihood of all-cause hospitalization (OR: 0.29).
  • The treatment reduced the risk of ICU admission (OR: 0.17) and mortality (OR: 0.15) within 30 days.
  • These benefits were observed in SOTR with mild-to-moderate COVID-19 symptoms.

Conclusions:

  • Monoclonal antibody therapy with sotrovimab demonstrates improved outcomes in SOTR.
  • Sotrovimab therapy is linked to a reduced risk of severe disease progression in this high-risk population.
  • Findings support sotrovimab as a valuable treatment option for COVID-19 in solid organ transplant recipients.
Keywords:
sotrovimabCOVID-19ICU admissionhospitalizationsolid organ transplant recipients

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.4K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

12.8K

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
186
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
624
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
241
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
74
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
417